Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Dow
Harvard Business School
Boehringer Ingelheim
Moodys

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR PERSANTINE


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Persantine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT02273531 ↗ Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox┬«; Extended Release) in Healthy Male and Female Volunteers Completed Boehringer Ingelheim Phase 1 2004-01-01 Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the present commercially available Asasantin ER formulation (Aggrenox┬«)
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Persantine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003018 ↗ S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer Completed National Cancer Institute (NCI) Phase 2 1997-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
NCT00003018 ↗ S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer Completed Southwest Oncology Group Phase 2 1997-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
NCT00763009 ↗ Persantine: Variation in Response Trial Terminated United States Department of Defense Phase 4 2002-09-01 The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.
NCT00763009 ↗ Persantine: Variation in Response Trial Terminated UConn Health Phase 4 2002-09-01 The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, blood tests and by measuring the flow of blood in the arteries of the heart in patients undergoing a clinically indicated percutaneous coronary intervention.
NCT00906035 ↗ The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD) Terminated Boehringer Ingelheim N/A 2002-09-01 This research study will evaluate the effects of aspirin and dipyridamole alone and in combination on the blood flow in the vessels of the legs. We will examine how these medications are able to inhibit the clotting of platelets in the vessels of patients with PAD, and thereby affect the blood flow in the legs. Platelets are cells in the blood that have the ability to adhere to each other to form clots.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Persantine

Condition Name

Condition Name for Persantine
Intervention Trials
Coronary Artery Disease 2
Healthy 2
Splenectomy 1
Venous Thrombosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Persantine
Intervention Trials
Coronary Disease 2
Coronary Artery Disease 2
Myocardial Ischemia 2
Purpura 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Persantine

Trials by Country

Trials by Country for Persantine
Location Trials
United States 29
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Persantine
Location Trials
Pennsylvania 2
Connecticut 2
Montana 1
New Mexico 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Persantine

Clinical Trial Phase

Clinical Trial Phase for Persantine
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
Phase 1/Phase 2 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Persantine
Clinical Trial Phase Trials
Completed 5
Terminated 2
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Persantine

Sponsor Name

Sponsor Name for Persantine
Sponsor Trials
Boehringer Ingelheim 3
Hartford Hospital 1
National Institute of Allergy and Infectious Diseases (NIAID) 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Persantine
Sponsor Trials
Other 12
Industry 4
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Harvard Business School
Colorcon
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.